Press Releases

Press Releases

    Date Title View
    05/24/22
    Summary ToggleHorizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology
    PDF Version
    05/17/22
    Summary ToggleHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
    PDF Version
    05/16/22
    Summary ToggleHorizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups
    PDF Version
    05/11/22
    Summary ToggleHorizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star
    PDF Version
    05/11/22
    Summary ToggleHorizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
    PDF Version
    05/09/22
    Summary ToggleHorizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
    PDF Version
    05/04/22
    Summary ToggleHorizon Therapeutics plc Reports First-Quarter 2022 Financial Results
    05/03/22
    Summary ToggleTopline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
    PDF Version
    05/02/22
    Summary ToggleHorizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community
    PDF Version
    05/02/22
    Summary ToggleHorizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    Displaying 1 - 10 of 655 results